Wegovy [injectable] for weight management) Tirzepatide (Mounjaro) is a related incretin-based therapy that acts as a dual GIP/GLP-1 receptor agonist
Deciding Whether Ongoing or Intermittent Tirzepatide Supports Your Goals Long-term success does not require lifelong tirzepatide treatment, but many patients benefit from continued or intermittent dosing
If you experience significant nausea or inability to eat during concurrent treatment, contact your provider, as dose adjustments or a brief semaglutide pause may help
They'll say something like "take your dose as soon as you remember, unless it's almost time for your next dose." This is wrong for semaglutide because the risks are asymmetric: Late dose (taken 1 to 2 days after scheduled day): Blood levels drop slightly below target Appetite suppression weakens temporarily No increased side effect risk No safety concern Easy fix: take the dose when you remember, resume normal schedule Early dose (taken 1 to 2 days before scheduled day): Blood levels rise slightly above target Appetite suppression unchanged Modest increase in GI side effect risk Generally safe for one-time occurrence Risk increases if it becomes a pattern The standard advice to "take it when you remember" works fine for late doses
For this drug, the ongoing SOUL trial has shown promising preliminary results, indicating a 14% reduction in the risk of MACE (84)